Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM: Lisocabtagene maraleucel vs Standard of Care in Second-line Transplant-eligible Aggressive B-cell Lymphoma
jRCT1080224646Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Phase 2, randomised trial in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, primary mediastinal large B-cell lymphoma (PMBCL) and 3 more comparing Lisocabtagene maraleucel arm with Standard of care arm (2 arms). Started Apr 2019; status: completed.
02
Drugs
lisocabtagene maraleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT1080224646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224646.